TRACON Pharmaceuticals announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment. “We are excited to announce the first license of our PDP to a company that recognizes the value of internalizing its clinical operations to reap the benefits of CRO-independent clinical trial implementation that we enjoy at TRACON,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We are now in a position to widely license our PDP to allow clinical stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines.” Under the terms of the Agreement, TRACON granted a non-exclusive and non-transferable license of its PDP to the clinical stage biotech company for the design, conduct and administration of clinical trials and related research and development activities, including activities relating to regulatory filings, submissions and approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCON:
- Biotech Alert: Searches spiking for these stocks today
- Tracon Pharmaceuticals reports Q3 EPS 29c, consensus (10c)
- TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- TCON Upcoming Earnings Report: What to Expect?
- TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023